XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $266K invested in XTL Biopharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
2% more capital invested
Capital invested by funds: $261K → $266K (+$4.7K)
0% more funds holding
Funds holding: 4 → 4 (0)
0.01% less ownership
Funds ownership: 2.08% → 2.07% (-0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.39K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$795 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $233K | – | – | – |
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $20.2K | – | – | – |
|
|
3
Morgan Stanley
New York
| $11.7K | -$1.39K | -250 | -9% |
|
|
4
UBS Group
Zurich,
Switzerland
| $893 | -$795 | -143 | -43% |
|
XTLB Hedge Fund Activity: Q3 2025 in Review
4 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2025, worth a combined $266K — up 1.8% from $261K a quarter earlier.
Fund positioning in XTLB was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Morgan Stanley, cutting an estimated $1.39K.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $266K of XTL Biopharmaceuticals stock for Q3 2025, up 1.8% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q3 2025 and 0 closed out.
- The largest XTL Biopharmaceuticals seller in Q3 2025 was Morgan Stanley, an estimated $1.39K sold.
Based on aggregated 13F filings for Q3 2025.